Study On Patient Support Program Impact Piques EMA's Interest
The pharmaceutical industry's renewed effort to find a pragmatic solution to managing adverse events from patient support programs has drawn the European Medicines Agency's attention.
You may also be interested in...
Changes to an ICH guideline could help drug companies that are being deluged with post-approval safety information to cut down on noisy, low-value data.
The European Medicines Agency wants to make it clearer for drug sponsors what more they can do to address the presence of cancer-causing impurities in active substances, and how to deal with the issue in their regulatory submissions.
A surge in scientific advice requests in the latter half of 2021 forced the European Medicines Agency to delay the start of some procedures, but the situation has improved considerably since then.